Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AL001 in Frontotemporal Dementia
NCT04374136Phase 3Terminated
- Sponsor
- Alector
- Start
- Jul 2020
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 16
01
Overview
Phase 3, randomised, double-blind trial of AL001 in frontotemporal dementia (FTD) (4 arms), sponsored by Alector. Primary endpoints: Clinical Dementia Rating plus National Alzheimer's Coordinating Center Frontotemporal Lobar Degeneration Sum of Boxes at 96 weeks, Pharmacodynamic and Disease Pathology Biomarkers at 96 weeks and 1 more. Started Jul 2020; status: terminated.
02
Drugs
AL001
03
Conditions
frontotemporal dementia (FTD)
Beyond the preview
Go deeper on NCT04374136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04374136.